secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-142019
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q1 net loss $14.7M; cash $292.1M; dosed first patient in ELVN-002 Phase 1
--------------------------------------------------------------------------------

- Net loss of $14.7M for Q1 2023 vs $8.7M in Q1 2022; R&D expenses $11.9M, G&A $4.5M.
- Cash and equivalents $292.1M as of March 31, 2023, expected to fund operations into early 2026.
- Dosed first patient in Phase 1 trial of ELVN-002 for HER2-altered NSCLC and other solid tumors.
- Enrollment progressing in Phase 1 trial of ELVN-001 for CML; initial safety/efficacy data expected in 2024.
- Completed merger with Imara Inc. in February 2023; shares now trade as ELVN on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523142019/0001193125-23-142019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523142019/d421860d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-142019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer